Cardiff Oncology Presents Novel Preclinical Data At AACR Annual Meeting 2024; Supports First-Line RAS-Mutated MCRC Clinical Study
Cardiff Oncology Presents Novel Preclinical Data At AACR Annual Meeting 2024; Supports First-Line RAS-Mutated MCRC Clinical Study
– In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and growth –
— 在RAS突变的mCRC中，新的临床前发现表明onvansertib抑制肿瘤适应缺氧的能力，从而显著降低肿瘤的血管形成和生长 —
– Enhanced clinical efficacy signal in bev naïve patients in Phase 1b/2 trial is consistent with results of randomized ONSEMBLE trial providing two independent data sets in second-line mCRC validating our strategy to evaluate onvansertib in combination with chemo/bev in RAS-mutated first-line mCRC –
— 在 1b/2 期试验中，bev naiève 患者的临床疗效信号增强与随机 ONSEMBLE 试验的结果一致，该试验在二线 mCRC 中提供了两个独立的数据集，验证了我们在RAS突变的一线 mCRC 中评估onvansertib与chemo/bev联合使用的策略 —
Therapeutic areas outside of RAS-mutated mCRC
Ras突变的 mCRC 以外的治疗区域
– In RAS-wild type mCRC, onvansertib demonstrates antitumor activity in preclinical models as a single agent and in combination with cetuximab, highlighting that onvansertib activity in mCRC can be independent of RAS mutational status –
— 在Ras-Wild型mCRC中，onvansertib作为单一药物在临床前模型中表现出抗肿瘤活性，并与西妥昔单抗联合使用，这突显了mCRC中的onvansertib活性可以与RAS突变状态无关 —
– In SCLC and ovarian cancer, robust preclinical data underscore onvansertib's activity in combination treatments across multiple tumors –
— 在小细胞肺癌和卵巢癌中，可靠的临床前数据凸显了onvansertib在多种肿瘤联合治疗中的活性 —